Directa Plus (DCTA) Share Price, News & Analysis

Company Overview

Directa Plus has a unique and patented, chemical-free production process of pristine graphene nanoplatelets (GNPs), tailored to our partners’ and customers’ requirements. The manufacturing model is flexible and scalable. We have a pioneering vision of the applications of G+® Graphene Plus in different industrial sectors. The markets where G+® is already at a commercial stage are: textile, environment, composites, elastomers and tires, battery and paints. Directa Plus launched the Graphehe Factory in 2010, an industrial plant able to produce up to 30 tonnes of different grades of G+® depending on the market’s needs. In 2017, we established an Advanced Development Area (ADA) composed of different laboratories to test and certify the performance quality of all our products. ADA team provides technical support to our clients and partners.

Key Stats

• Today's Range: 6 to 6.50
• 50-Day Range: 6 to 10.50
• 52-Week Range: 6 to 24.05
• Volume: 19,773 shs
• Average Volume: 53,698 shs
• Market Capitalization: £6.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DCTA Stock Analysis - Frequently Asked Questions

How have DCTA shares performed this year?

Directa Plus' stock was trading at GBX 6.50 at the beginning of the year. Since then, DCTA stock has decreased by 7.7% and is now trading at GBX 6.
View the best growth stocks for 2025 here.

How do I buy shares of Directa Plus?

Shares of DCTA stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Directa Plus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Directa Plus investors own include Indivior (INDV), Advanced Accelerator Applications (AAAP), Editas Medicine (EDIT), MGT Capital Investments (MGTI), Biglari (BH), Bigblu Broadband (BBB) and Futura Medical (FUM).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Basic Materials
• Industry: Specialty Chemicals
• Sub-Industry: N/A
• Current Symbol: LON:DCTA
• CUSIP: N/A
• CIK: N/A
• Web: www.directa-plus.com
• Phone: 39 02 36 71 44 00
• Fax: N/A
• Employees: 187
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 4.71
• P/E Growth: N/A
• Net Income: £-4,480,000.00
• Net Margins: -48.00%
• Pretax Margin: N/A
• Return on Equity: -67.15%
• Return on Assets: -22.41%

Debt

• Debt-to-Equity Ratio: 57.75
• Current Ratio: 1.50
• Quick Ratio: 4.88

Sales & Book Value

• Annual Sales: £9.33 million
• Price / Sales: 0.67
• Cash Flow: GBX 0.80 per share
• Price / Cash Flow: 7.51
• Book Value: GBX 7 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 104,420,000
• Free Float: N/A
• Market Cap: £6.27 million
• Optionable: Not Optionable
• Beta: 0.74